论文部分内容阅读
目的:探讨左炔诺孕酮宫内缓释系统(LNG-IUS;商品名:曼月乐)在治疗围绝经期子宫腺肌病中的临床疗效。方法:对67例确诊的围绝经期子宫腺肌病患者宫内放置曼月乐,随访放置后在痛经程度、经量、经期及血清CA125、基础内分泌、围绝经期症状等临床指标的变化。结果:放置曼月乐后痛经症状明显缓解,经量明显减少,经期缩短,差异有统计学意义(P<0.01),放置后6个月血清CA125明显降低,差异有统计学意义(P<0.05),基础内分泌指标(FSH、LH、E2)以及围绝经期症状在放置前后无明显变化,差异无统计学意义(P>0.05)。结论:曼月乐治疗围绝经期子宫腺肌病疗效可观,值得临床推广。
Objective: To investigate the clinical efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS; trade name: Mirena L) in the treatment of perimenopausal adenomyosis. Methods: Mirena was placed in the uterus of 67 patients with confirmed perimenopausal adenomyosis, and their clinical features including dysmenorrhea, menstrual flow, menstrual flow, serum CA125, basal endocrine and perimenopausal symptoms were observed after placement. Results: The symptoms of dysmenorrhea were relieved obviously after Mirena was placed, the amount of menstruation was significantly reduced and menstruation was shortened, the difference was statistically significant (P <0.01), and the serum CA125 was significantly lower at 6 months after placement ), Basal endocrine indicators (FSH, LH, E2) and perimenopausal symptoms before and after placement had no significant change, the difference was not statistically significant (P> 0.05). Conclusion: Mirena music treatment of perimenopausal adenomyosis significant effect, worthy of clinical promotion.